Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(OP: RLFTD )

N/A UNCHANGED
Last Price Updated: 3:36 PM EST, Nov 29, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 6.250
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Relief Therapeutics Reports Half-Year 2023 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Relief Therapeutics Announces New Exclusive Definitive License Agreement for OLPRUVA(TM) (ACER-001) with Acer Therapeutics
Via ACCESSWIRE

Performance

More News

Read More
Relief Therapeutics and World Orphan Drug Alliance Announce an Exclusive, Long-Term, Distribution Agreement to Introduce PKU GOLIKE(R) in the Middle East
Via ACCESSWIRE
RELIEF THERAPEUTICS Holding SA Announces Closing of CHF 5 Million Private Placement
Via ACCESSWIRE
RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting of Shareholders
Via ACCESSWIRE
RELIEF THERAPEUTICS Holding SA Announces CHF 5 Million Private Placement
Via ACCESSWIRE
Relief Therapeutics Announces Executive Leadership Team Changes
Via ACCESSWIRE
Relief Therapeutics Announces Six-Month Stability Data on a New Formulation of RLF-100 (Aviptadil)
Via ACCESSWIRE
RELIEF THERAPEUTICS Holding SA Announces Notice of Annual General Meeting of Shareholders
Via ACCESSWIRE
Relief Therapeutics Announces Issuance of Shares from Authorized Capital
Via ACCESSWIRE
APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival
Via ACCESSWIRE
Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission
Via ACCESSWIRE
Relief Therapeutics, NRx Pharma Settle Litigation Regarding COVID-19 Treatment Candidate
Via Benzinga
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements
Via ACCESSWIRE
Relief Therapeutics Holding SA and NRx Pharmaceuticals, inc. Further Extend their Stay of Pending Litigation to Provide Additional Time for the Parties to Finalize their Litigation Settlement
Via ACCESSWIRE
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.